eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
3/2013
vol. 38
 
Share:
Share:
abstract:

Review paper
Toll-like receptor 4 polymorphisms and susceptibility to multiple autoimmune diseases: evidence based on pooled analysis

Xiao-qin Wang
,
Kui Zhang
,
Ding Xiong

(Centr Eur J Immunol 2013; 38 (3): 380-387)
Online publish date: 2013/10/28
View full text Get citation
 
PlumX metrics:
Background: Toll-like receptor 4 (TLR4) is known to activate the nuclear factor B (NF-B) and subsequent gene expression such as cytokines and adhesion molecules. That may subsequently reduce the risk of autoimmune diseases (ADs). However, the results of molecular epidemiological studies remain inconsistent.

Material and methods: The PubMed, Embase, CNKI databases were searched for all articles available. The OR corresponding to the 95% confidence interval (95% CI) was used to assess the association between TLR4 polymorphisms and the risk of ADs.

Results: The TLR4 Asp299Gly and TLR4 Thr399Ile polymorphisms were not associated significantly with a risk of ADs (Asp299Gly: OR = 0.86, 95% CI: 0.74-1.00 for G vs. A and OR = 0.87, 95% CI: 0.74-1.01 for AG/GG vs. AA, respectively; Thr399Ile: OR = 0.77, 95% CI: 0.57-1.05 for T vs. C and OR = 0.79, 95% CI: 0.58-1.09 for TT/CT vs. CC, respectively).

Conclusions: This meta-analysis suggested that TLR4 Asp299Gly and TLR4 Thr399Ile polymorphisms were not involved in the development of ADs. However, well-designed studies with a larger sample size should be conducted to confirm this result.
keywords:

autoimmune diseases, Toll-like receptor 4, single nucleotide polymorphism, meta-analysis, SNP

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.